BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Catenacci DV. Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity. Mol Oncol. 2015;9:967-996. [PMID: 25557400 DOI: 10.1016/j.molonc.2014.09.011] [Cited by in Crossref: 93] [Cited by in F6Publishing: 79] [Article Influence: 11.6] [Reference Citation Analysis]
Number Citing Articles
1 Catenacci DV, Ang A, Liao WL, Shen J, O'Day E, Loberg RD, Cecchi F, Hembrough T, Ruzzo A, Graziano F. MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma. Cancer 2017;123:1061-70. [PMID: 27926778 DOI: 10.1002/cncr.30437] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
2 Wu W, Li X, Yu S. Patient-derived Tumour Organoids (PDOs): A Bridge between Cancer Biology and Personalised Therapy. Acta Biomaterialia 2022. [DOI: 10.1016/j.actbio.2022.04.050] [Reference Citation Analysis]
3 Snowdon C, Kernaghan S, Moretti L, Turner NC, Ring A, Wilkinson K, Martin S, Foster S, Kilburn LS, Bliss JM. Operational complexity versus design efficiency: challenges of implementing a phase IIa multiple parallel cohort targeted treatment platform trial in advanced breast cancer. Trials 2022;23:372. [PMID: 35526005 DOI: 10.1186/s13063-022-06312-x] [Reference Citation Analysis]
4 Sequiera GL, Srivastava A, Sareen N, Yan W, Alagarsamy KN, Verma E, Aghanoori MR, Aliani M, Kumar A, Fernyhough P, Rockman-Greenberg C, Dhingra S. Development of iPSC-based clinical trial selection platform for patients with ultrarare diseases. Sci Adv 2022;8:eabl4370. [PMID: 35394834 DOI: 10.1126/sciadv.abl4370] [Reference Citation Analysis]
5 Barroilhet L, Matulonis U. The NCI-MATCH trial and precision medicine in gynecologic cancers. Gynecologic Oncology 2018;148:585-90. [DOI: 10.1016/j.ygyno.2018.01.008] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 7.8] [Reference Citation Analysis]
6 Kourie HR, Aoun F. Why balls are not put inside the basket? A reflection on testicular cancer clinical trial design. Invest New Drugs 2016;34:513-4. [PMID: 26960332 DOI: 10.1007/s10637-016-0338-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
7 Luen S, Virassamy B, Savas P, Salgado R, Loi S. The genomic landscape of breast cancer and its interaction with host immunity. Breast. 2016;29:241-250. [PMID: 27481651 DOI: 10.1016/j.breast.2016.07.015] [Cited by in Crossref: 104] [Cited by in F6Publishing: 93] [Article Influence: 20.8] [Reference Citation Analysis]
8 Syn NL, Yong WP, Goh BC, Lee SC. Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review. Expert Opin Drug Metab Toxicol 2016;12:911-22. [PMID: 27249175 DOI: 10.1080/17425255.2016.1196187] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 6.3] [Reference Citation Analysis]
9 Mansinho A, Boni V, de Miguel M, Calvo E. The future of oncology therapeutics. Expert Rev Anticancer Ther 2017;17:563-5. [PMID: 28504011 DOI: 10.1080/14737140.2017.1331131] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
10 Prasad V, Vandross A. Characteristics of Exceptional or Super Responders to Cancer Drugs. Mayo Clin Proc 2015;90:1639-49. [PMID: 26546106 DOI: 10.1016/j.mayocp.2015.08.017] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
11 Madhavan S, Subramaniam S, Brown TD, Chen JL. Art and Challenges of Precision Medicine: Interpreting and Integrating Genomic Data Into Clinical Practice. Am Soc Clin Oncol Educ Book 2018;38:546-53. [PMID: 30231369 DOI: 10.1200/EDBK_200759] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
12 Foo MA, You M, Chan SL, Sethi G, Bonney GK, Yong WP, Chow EK, Fong ELS, Wang L, Goh BC. Clinical translation of patient-derived tumour organoids- bottlenecks and strategies. Biomark Res 2022;10:10. [PMID: 35272694 DOI: 10.1186/s40364-022-00356-6] [Reference Citation Analysis]
13 Maron SB, Catenacci DVT. Update on Gastroesophageal Adenocarcinoma Targeted Therapies. Hematol Oncol Clin North Am 2017;31:511-27. [PMID: 28501091 DOI: 10.1016/j.hoc.2017.01.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
14 Thabane L, Lancaster G. Improving the efficiency of trials using innovative pilot designs: the next phase in the conduct and reporting of pilot and feasibility studies. Pilot Feasibility Stud 2018;4:14. [PMID: 28694993 DOI: 10.1186/s40814-017-0159-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
15 Moore KN, Mannel RS. Is the NCI MATCH trial a match for gynecologic oncology? Gynecol Oncol 2016;140:161-6. [PMID: 26586415 DOI: 10.1016/j.ygyno.2015.11.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
16 Pei S, Minhajuddin M, D'Alessandro A, Nemkov T, Stevens BM, Adane B, Khan N, Hagen FK, Yadav VK, De S, Ashton JM, Hansen KC, Gutman JA, Pollyea DA, Crooks PA, Smith C, Jordan CT. Rational Design of a Parthenolide-based Drug Regimen That Selectively Eradicates Acute Myelogenous Leukemia Stem Cells. J Biol Chem 2016;291:21984-2000. [PMID: 27573247 DOI: 10.1074/jbc.M116.750653] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
17 Ouma LO, Grayling MJ, Zheng H, Wason J. Treatment allocation strategies for umbrella trials in the presence of multiple biomarkers: A comparison of methods. Pharm Stat 2021. [PMID: 33759353 DOI: 10.1002/pst.2119] [Reference Citation Analysis]
18 Ajani JA, Lee J, Sano T, Janjigian YY, Fan D, Song S. Gastric adenocarcinoma. Nat Rev Dis Primers. 2017;3:17036. [PMID: 28569272 DOI: 10.1038/nrdp.2017.36] [Cited by in Crossref: 178] [Cited by in F6Publishing: 184] [Article Influence: 35.6] [Reference Citation Analysis]
19 Bhattacharya I, Heatherington A, Barton J. Applying the best of oncology drug development paradigms to the non-malignant space. Drug Discov Today 2016;21:1869-72. [PMID: 27393488 DOI: 10.1016/j.drudis.2016.06.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
20 Catenacci DV, Junttila MR, Karrison T, Bahary N, Horiba MN, Nattam SR, Marsh R, Wallace J, Kozloff M, Rajdev L, Cohen D, Wade J, Sleckman B, Lenz HJ, Stiff P, Kumar P, Xu P, Henderson L, Takebe N, Salgia R, Wang X, Stadler WM, de Sauvage FJ, Kindler HL. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. J Clin Oncol. 2015;33:4284-4292. [PMID: 26527777 DOI: 10.1200/jco.2015.62.8719] [Cited by in Crossref: 266] [Cited by in F6Publishing: 172] [Article Influence: 38.0] [Reference Citation Analysis]
21 Silva A, Silva MC, Sudalagunta P, Distler A, Jacobson T, Collins A, Nguyen T, Song J, Chen DT, Chen L, Cubitt C, Baz R, Perez L, Rebatchouk D, Dalton W, Greene J, Gatenby R, Gillies R, Sontag E, Meads MB, Shain KH. An Ex Vivo Platform for the Prediction of Clinical Response in Multiple Myeloma. Cancer Res 2017;77:3336-51. [PMID: 28400475 DOI: 10.1158/0008-5472.CAN-17-0502] [Cited by in Crossref: 38] [Cited by in F6Publishing: 17] [Article Influence: 7.6] [Reference Citation Analysis]
22 Bitterman DS, Cagney DN, Singer LL, Nguyen PL, Catalano PJ, Mak RH. Master Protocol Trial Design for Efficient and Rational Evaluation of Novel Therapeutic Oncology Devices. J Natl Cancer Inst 2020;112:229-37. [PMID: 31504680 DOI: 10.1093/jnci/djz167] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
23 Rojas V, Hirshfield KM, Ganesan S, Rodriguez-Rodriguez L. Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment. Int J Mol Sci 2016;17:E2113. [PMID: 27983698 DOI: 10.3390/ijms17122113] [Cited by in Crossref: 76] [Cited by in F6Publishing: 74] [Article Influence: 12.7] [Reference Citation Analysis]
24 Liu CY, Wu CY, Petrossian K, Huang TT, Tseng LM, Chen S. Treatment for the endocrine resistant breast cancer: Current options and future perspectives. J Steroid Biochem Mol Biol 2017;172:166-75. [PMID: 28684381 DOI: 10.1016/j.jsbmb.2017.07.001] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
25 Mukasa A. Genome Medicine for Brain Tumors: Current Status and Future Perspectives. Neurol Med Chir (Tokyo) 2020;60:531-42. [PMID: 33071276 DOI: 10.2176/nmc.ra.2020-0175] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Lomnicki S, Setia N, Catenacci DVT. Tackling diversity within diversity. Ann Oncol 2020;31:970-2. [PMID: 32454070 DOI: 10.1016/j.annonc.2020.05.013] [Reference Citation Analysis]
27 Huang M, Hunter T, Slomovitz B, Schlumbrecht M. Impact of molecular testing in clinical practice in gynecologic cancers. Cancer Med 2019;8:2013-9. [PMID: 30848097 DOI: 10.1002/cam4.2064] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
28 Abdo J, Bertellotti CA, Cornell DL, Agrawal DK, Mittal SK. Neoadjuvant Therapy for Esophageal Adenocarcinoma in the Community Setting-Practice and Outcomes. Front Oncol 2017;7:151. [PMID: 28770168 DOI: 10.3389/fonc.2017.00151] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
29 Garattini S, Fuso Nerini I, D'Incalci M. Not only tumor but also therapy heterogeneity. Ann Oncol 2018;29:13-9. [PMID: 29045538 DOI: 10.1093/annonc/mdx646] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
30 Maron SB, Alpert L, Kwak HA, Lomnicki S, Chase L, Xu D, O'Day E, Nagy RJ, Lanman RB, Cecchi F, Hembrough T, Schrock A, Hart J, Xiao SY, Setia N, Catenacci DVT. Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma. Cancer Discov 2018;8:696-713. [PMID: 29449271 DOI: 10.1158/2159-8290.CD-17-1260] [Cited by in Crossref: 62] [Cited by in F6Publishing: 37] [Article Influence: 15.5] [Reference Citation Analysis]
31 Secord AA, Previs RA, Nixon AB. Cabozantinib in ovarian clear cell cancers: UnMET expectations. Gynecol Oncol 2018;150:1-2. [PMID: 29935857 DOI: 10.1016/j.ygyno.2018.06.006] [Reference Citation Analysis]
32 Lewis JR, Kerridge I, Lipworth W. Use of Real-World Data for the Research, Development, and Evaluation of Oncology Precision Medicines. JCO Precision Oncology 2017. [DOI: 10.1200/po.17.00157] [Cited by in Crossref: 8] [Article Influence: 1.6] [Reference Citation Analysis]
33 Renfro LA, Sargent DJ. Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. Ann Oncol 2017;28:34-43. [PMID: 28177494 DOI: 10.1093/annonc/mdw413] [Cited by in Crossref: 130] [Cited by in F6Publishing: 110] [Article Influence: 32.5] [Reference Citation Analysis]
34 Guo W, Ji Y, Catenacci DVT. A subgroup cluster-based Bayesian adaptive design for precision medicine. Biometrics 2017;73:367-77. [PMID: 27775814 DOI: 10.1111/biom.12613] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
35 Tan AC, Vyse S, Huang PH. Exploiting receptor tyrosine kinase co-activation for cancer therapy. Drug Discov Today 2017;22:72-84. [PMID: 27452454 DOI: 10.1016/j.drudis.2016.07.010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
36 Hernandez-martinez J, Sánchez-reyes R, De la Garza-salazar JG, Arrieta O. Onco-omics Approaches and Applications in Clinical Trials for Cancer Patients. In: Ruiz-garcia E, Astudillo-de la Vega H, editors. Translational Research and Onco-Omics Applications in the Era of Cancer Personal Genomics. Cham: Springer International Publishing; 2019. pp. 79-90. [DOI: 10.1007/978-3-030-24100-1_5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
37 Pectasides E, Stachler MD, Derks S, Liu Y, Maron S, Islam M, Alpert L, Kwak H, Kindler H, Polite B, Sharma MR, Allen K, O'Day E, Lomnicki S, Maranto M, Kanteti R, Fitzpatrick C, Weber C, Setia N, Xiao SY, Hart J, Nagy RJ, Kim KM, Choi MG, Min BH, Nason KS, O'Keefe L, Watanabe M, Baba H, Lanman R, Agoston AT, Oh DJ, Dunford A, Thorner AR, Ducar MD, Wollison BM, Coleman HA, Ji Y, Posner MC, Roggin K, Turaga K, Chang P, Hogarth K, Siddiqui U, Gelrud A, Ha G, Freeman SS, Rhoades J, Reed S, Gydush G, Rotem D, Davison J, Imamura Y, Adalsteinsson V, Lee J, Bass AJ, Catenacci DV. Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discov. 2018;8:37-48. [PMID: 28978556 DOI: 10.1158/2159-8290.cd-17-0395] [Cited by in Crossref: 128] [Cited by in F6Publishing: 78] [Article Influence: 25.6] [Reference Citation Analysis]
38 Campbell J, King NB. “Unsettling circularity”: Clinical trial enrichment and the evidentiary politics of chronic pain. BioSocieties 2017;12:191-216. [DOI: 10.1057/biosoc.2016.7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
39 Aust S, Schwameis R, Gagic T, Müllauer L, Langthaler E, Prager G, Grech C, Reinthaller A, Krainer M, Pils D, Grimm C, Polterauer S. Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer. Cancers (Basel) 2020;12:E548. [PMID: 32120793 DOI: 10.3390/cancers12030548] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
40 Ling S, Hu Z, Yang Z, Yang F, Li Y, Lin P, Chen K, Dong L, Cao L, Tao Y, Hao L, Chen Q, Gong Q, Wu D, Li W, Zhao W, Tian X, Hao C, Hungate EA, Catenacci DV, Hudson RR, Li WH, Lu X, Wu CI. Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution. Proc Natl Acad Sci USA. 2015;112:E6496-E6505. [PMID: 26561581 DOI: 10.1073/pnas.1519556112] [Cited by in Crossref: 237] [Cited by in F6Publishing: 188] [Article Influence: 33.9] [Reference Citation Analysis]
41 Sonnenblick A, Pondé N, Piccart M. Metastatic breast cancer: The Odyssey of personalization. Mol Oncol 2016;10:1147-59. [PMID: 27430154 DOI: 10.1016/j.molonc.2016.07.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
42 McBride M, Rida PC, Aneja R. Turning the headlights on novel cancer biomarkers: Inspection of mechanics underlying intratumor heterogeneity. Mol Aspects Med 2015;45:3-13. [PMID: 26024970 DOI: 10.1016/j.mam.2015.05.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
43 Maron SB, Chase LM, Lomnicki S, Kochanny S, Moore KL, Joshi SS, Landron S, Johnson J, Kiedrowski LA, Nagy RJ, Lanman RB, Kim ST, Lee J, Catenacci DVT. Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma. Clin Cancer Res 2019;25:7098-112. [PMID: 31427281 DOI: 10.1158/1078-0432.CCR-19-1704] [Cited by in Crossref: 44] [Cited by in F6Publishing: 23] [Article Influence: 14.7] [Reference Citation Analysis]
44 Lai TS, Manrriquez E, Neal A, Memarzadeh S. Matched sequential tumor molecular profiling in solid malignancies may impact clinical practice. Cancer Genet 2021;252-253:73-9. [PMID: 33434795 DOI: 10.1016/j.cancergen.2020.12.008] [Reference Citation Analysis]
45 Jacobson RA, Munding E, Hayden DM, Levy M, Kuzel TM, Pappas SG, Masood A. Evolving Clinical Utility of Liquid Biopsy in Gastrointestinal Cancers. Cancers (Basel) 2019;11:E1164. [PMID: 31412682 DOI: 10.3390/cancers11081164] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
46 Kouba EJ, Eble JN, Simper N, Grignon DJ, Wang M, Zhang S, Wang L, Martignoni G, Williamson SR, Brunelli M, Luchini C, Calió A, Cheng L. High fidelity of driver chromosomal alterations among primary and metastatic renal cell carcinomas: implications for tumor clonal evolution and treatment. Mod Pathol 2016;29:1347-57. [DOI: 10.1038/modpathol.2016.133] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
47 Meyer EL, Mesenbrink P, Dunger-baldauf C, Fülle H, Glimm E, Li Y, Posch M, König F. The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review. Clinical Therapeutics 2020;42:1330-60. [DOI: 10.1016/j.clinthera.2020.05.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
48 Coyne GO, Takebe N, Chen AP. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH. Current Problems in Cancer 2017;41:182-93. [DOI: 10.1016/j.currproblcancer.2017.02.001] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 11.2] [Reference Citation Analysis]
49 Vincenzi B, Imperatori M, Silletta M, Marrucci E, Santini D, Tonini G. Emerging kinase inhibitors of the treatment of gastric cancer. Expert Opin Emerg Drugs 2015;20:479-93. [PMID: 26021342 DOI: 10.1517/14728214.2015.1051467] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
50 McQuerry JA, Chang JT, Bowtell DDL, Cohen A, Bild AH. Mechanisms and clinical implications of tumor heterogeneity and convergence on recurrent phenotypes. J Mol Med (Berl) 2017;95:1167-78. [PMID: 28871446 DOI: 10.1007/s00109-017-1587-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
51 Klempner SJ, Madison R, Pujara V, Ross JS, Miller VA, Ali SM, Schrock AB, Kim ST, Maron SB, Dayyani F, Catenacci DVT, Lee J, Chao J. FGFR2-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape. Oncologist 2019;24:1462-8. [PMID: 31249137 DOI: 10.1634/theoncologist.2019-0121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
52 Catenacci DV, Tesfaye A, Tejani M, Cheung E, Eisenberg P, Scott AJ, Eng C, Hnatyszyn J, Marina N, Powers J, Wainberg Z. Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design. Future Oncol 2019;15:2073-82. [PMID: 31094225 DOI: 10.2217/fon-2019-0141] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 6.7] [Reference Citation Analysis]
53 Catenacci DVT. When Inhibitor MET Biomarker: Postmortem or Initium Novum? JCO Precis Oncol 2019;3. [PMID: 30997444 DOI: 10.1200/PO.18.00359] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
54 Chin-Yee B, Subramanian SV, Verma AA, Laupacis A, Razak F. Emerging Trends in Clinical Research: With Implications for Population Health and Health Policy. Milbank Q 2018;96:369-401. [PMID: 29870114 DOI: 10.1111/1468-0009.12328] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
55 Jakoby J, Beuschlein F, Mentz S, Hantel C, Süss R. Liposomal doxorubicin for active targeting: surface modification of the nanocarrier evaluated in vitro and in vivo: challenges and prospects. Oncotarget 2015;6:43698-711. [PMID: 26497207 DOI: 10.18632/oncotarget.6191] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
56 Catenacci DVT, Moya S, Lomnicki S, Chase LM, Peterson BF, Reizine N, Alpert L, Setia N, Xiao SY, Hart J, Siddiqui UD, Hogarth DK, Eng OS, Turaga K, Roggin K, Posner MC, Chang P, Narula S, Rampurwala M, Ji Y, Karrison T, Liao CY, Polite BN, Kindler HL. Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. Cancer Discov 2021;11:308-25. [PMID: 33234578 DOI: 10.1158/2159-8290.CD-20-1408] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
57 Anisuzzaman AS, Haque A, Rahman MA, Wang D, Fuchs JR, Hurwitz S, Liu Y, Sica G, Khuri FR, Chen ZG, Shin DM, Amin AR. Preclinical In Vitro, In Vivo, and Pharmacokinetic Evaluations of FLLL12 for the Prevention and Treatment of Head and Neck Cancers. Cancer Prev Res (Phila) 2016;9:63-73. [PMID: 26511491 DOI: 10.1158/1940-6207.CAPR-15-0240] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
58 Page R, Baneux P, Vail D, Duda L, Olson P, Anestidou L, Dybdal N, Golab G, Shelton W, Salgaller M, Hardy C. Conduct, Oversight, and Ethical Considerations of Clinical Trials in Companion Animals with Cancer: Report of a Workshop on Best Practice Recommendations. J Vet Intern Med 2016;30:527-35. [PMID: 26950524 DOI: 10.1111/jvim.13916] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
59 Hudler P. Challenges of deciphering gastric cancer heterogeneity. World J Gastroenterol 2015; 21(37): 10510-10527 [PMID: 26457012 DOI: 10.3748/wjg.v21.i37.10510] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 33] [Article Influence: 5.1] [Reference Citation Analysis]
60 Kimbrough CW, Khanal A, Zeiderman M, Khanal BR, Burton NC, McMasters KM, Vickers SM, Grizzle WE, McNally LR. Targeting Acidity in Pancreatic Adenocarcinoma: Multispectral Optoacoustic Tomography Detects pH-Low Insertion Peptide Probes In Vivo. Clin Cancer Res 2015;21:4576-85. [PMID: 26124201 DOI: 10.1158/1078-0432.CCR-15-0314] [Cited by in Crossref: 42] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
61 Catenacci DV. Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity. Mol Oncol. 2015;9:967-996. [PMID: 25557400 DOI: 10.1016/j.molonc.2014.09.011] [Cited by in Crossref: 93] [Cited by in F6Publishing: 79] [Article Influence: 11.6] [Reference Citation Analysis]
62 Berns A, Ringborg U, Celis JE, Heitor M, Aaronson NK, Abou-Zeid N, Adami HO, Apostolidis K, Baumann M, Bardelli A, Bernards R, Brandberg Y, Caldas C, Calvo F, Dive C, Eggert A, Eggermont A, Espina C, Falkenburg F, Foucaud J, Hanahan D, Helbig U, Jönsson B, Kalager M, Karjalainen S, Kásler M, Kearns P, Kärre K, Lacombe D, de Lorenzo F, Meunier F, Nettekoven G, Oberst S, Nagy P, Philip T, Price R, Schüz J, Solary E, Strang P, Tabernero J, Voest E. Towards a cancer mission in Horizon Europe: recommendations. Mol Oncol 2020;14:1589-615. [PMID: 32749074 DOI: 10.1002/1878-0261.12763] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 14.0] [Reference Citation Analysis]
63 Shankar-Hari M, Rubenfeld GD. Population enrichment for critical care trials: phenotypes and differential outcomes. Curr Opin Crit Care 2019;25:489-97. [PMID: 31335383 DOI: 10.1097/MCC.0000000000000641] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 8.5] [Reference Citation Analysis]
64 Zugazagoitia J, Guedes C, Ponce S, Ferrer I, Molina-Pinelo S, Paz-Ares L. Current Challenges in Cancer Treatment. Clin Ther 2016;38:1551-66. [PMID: 27158009 DOI: 10.1016/j.clinthera.2016.03.026] [Cited by in Crossref: 221] [Cited by in F6Publishing: 185] [Article Influence: 36.8] [Reference Citation Analysis]
65 Lee J, Bass AJ, Ajani JA. Gastric Adenocarcinoma: An Update on Genomics, Immune System Modulations, and Targeted Therapy. American Society of Clinical Oncology Educational Book 2016. [DOI: 10.1200/edbk_159091] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
66 Le Tourneau C, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, Campone M, Trédan O, Massiani MA, Mauborgne C. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015;16:1324-1334. [PMID: 26342236 DOI: 10.1016/s1470-2045(15)00188-6] [Cited by in Crossref: 594] [Cited by in F6Publishing: 323] [Article Influence: 84.9] [Reference Citation Analysis]
67 Abdo J, Agrawal DK, Mittal SK. Basis for molecular diagnostics and immunotherapy for esophageal cancer. Expert Rev Anticancer Ther 2017;17:33-45. [PMID: 27838937 DOI: 10.1080/14737140.2017.1260449] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
68 Catenacci DV. Expansion platform type II: testing a treatment strategy. Lancet Oncol 2015;16:1276-8. [PMID: 26342235 DOI: 10.1016/S1470-2045(15)00224-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
69 Janiaud P, Serghiou S, Ioannidis JP. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology. Cancer Treatment Reviews 2019;73:20-30. [DOI: 10.1016/j.ctrv.2018.12.003] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 17.3] [Reference Citation Analysis]
70 Catenacci DVT, Chase L, Lomnicki S, Karrison T, de Wilton Marsh R, Rampurwala MM, Narula S, Alpert L, Setia N, Xiao SY, Hart J, Siddiqui UD, Peterson B, Moore K, Kipping-Johnson K, Markevicius U, Gordon B, Allen K, Racette C, Maron SB, Liao CY, Polite BN, Kindler HL, Turaga K, Prachand VN, Roggin KK, Ferguson MK, Posner MC. Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Netw Open 2020;3:e1921290. [PMID: 32058557 DOI: 10.1001/jamanetworkopen.2019.21290] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
71 Manne U, Jadhav T, Putcha BK, Samuel T, Soni S, Shanmugam C, Suswam EA. Molecular Biomarkers of Colorectal Cancer and Cancer Disparities: Current Status and Perspective. Curr Colorectal Cancer Rep 2016;12:332-44. [PMID: 28626361 DOI: 10.1007/s11888-016-0338-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
72 Zhang SQ, Catenacci DV. How can next-generation diagnostics aid pancreatic adenocarcinoma treatment? Future Oncology 2016;12:585-8. [DOI: 10.2217/fon.15.353] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
73 Mathé E, Hays JL, Stover DG, Chen JL. The Omics Revolution Continues: The Maturation of High-Throughput Biological Data Sources. Yearb Med Inform 2018;27:211-22. [PMID: 30157526 DOI: 10.1055/s-0038-1667085] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
74 Gunderson CC, Rowland MR, Wright DL, Andrade KL, Mannel RS, McMeekin DS, Moore KN. Initiation of a formalized precision medicine program in gynecologic oncology. Gynecol Oncol 2016;141:24-8. [PMID: 27016225 DOI: 10.1016/j.ygyno.2016.02.024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
75 Burd A, Schilsky RL, Byrd JC, Levine RL, Papadimitrakopoulou VA, Herbst RS, Redman MW, Druker BJ, Gandara DR. Challenges and approaches to implementing master/basket trials in oncology. Blood Adv 2019;3:2237-43. [PMID: 31337605 DOI: 10.1182/bloodadvances.2019031229] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
76 Si H, Du D, Li W, Li Q, Li J, Zhao D, Li L, Tang B. Sputum-Based Tumor Fluid Biopsy: Isolation and High-Throughput Single-Cell Analysis of Exfoliated Tumor Cells for Lung Cancer Diagnosis. Anal Chem 2021;93:10477-86. [PMID: 34292723 DOI: 10.1021/acs.analchem.1c00833] [Reference Citation Analysis]
77 Maron SB, Catenacci DV. Novel Targeted Therapies for Esophagogastric Cancer. Surg Oncol Clin N Am. 2017;26:293-312. [PMID: 28279470 DOI: 10.1016/j.soc.2016.10.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
78 Cejalvo JM, Gambardella V, Fleitas T, Cervantes A. In the literature: February 2021. ESMO Open 2021;6:100061. [PMID: 33639602 DOI: 10.1016/j.esmoop.2021.100061] [Reference Citation Analysis]
79 Hirakawa A, Asano J, Sato H, Teramukai S. Master protocol trials in oncology: Review and new trial designs. Contemp Clin Trials Commun 2018;12:1-8. [PMID: 30182068 DOI: 10.1016/j.conctc.2018.08.009] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 10.5] [Reference Citation Analysis]
80 Renfro LA, Mandrekar SJ. Definitions and statistical properties of master protocols for personalized medicine in oncology. Journal of Biopharmaceutical Statistics 2018;28:217-28. [DOI: 10.1080/10543406.2017.1372778] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
81 Ruan Y, Narendran A. Response to "Insulin-like growth factor 1 receptor signaling via Akt: a general therapeutic target in neurocutaneous melanocytosis?". Neuro Oncol 2016;18:143-4. [PMID: 26667140 DOI: 10.1093/neuonc/nov290] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
82 Catenacci DVT, Liao WL, Zhao L, Whitcomb E, Henderson L, O'Day E, Xu P, Thyparambil S, Krizman D, Bengali K, Uzzell J, Darfler M, Cecchi F, Blackler A, Bang YJ, Hart J, Xiao SY, Lee SM, Burrows J, Hembrough T. Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH. Gastric Cancer 2016;19:1066-79. [PMID: 26581548 DOI: 10.1007/s10120-015-0566-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
83 Catani JPP, Riechelmann RP, Adjemian S, Strauss BE. Near future of tumor immunology: Anticipating resistance mechanisms to immunotherapies, a big challenge for clinical trials. Hum Vaccin Immunother 2017;13:1109-11. [PMID: 28059608 DOI: 10.1080/21645515.2016.1269046] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
84 Musolino A, Campone M, Neven P, Denduluri N, Barrios CH, Cortes J, Blackwell K, Soliman H, Kahan Z, Bonnefoi H, Squires M, Zhang Y, Deudon S, Shi MM, André F. Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy. Breast Cancer Res 2017;19:18. [PMID: 28183331 DOI: 10.1186/s13058-017-0807-8] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 11.0] [Reference Citation Analysis]
85 Myklebost O. Personalized cancer therapy for soft tissue sarcomas: progress and pitfalls. Per Med 2015;12:593-602. [PMID: 29750616 DOI: 10.2217/pme.15.20] [Reference Citation Analysis]
86 LeSavage BL, Suhar RA, Broguiere N, Lutolf MP, Heilshorn SC. Next-generation cancer organoids. Nat Mater 2021. [PMID: 34385685 DOI: 10.1038/s41563-021-01057-5] [Reference Citation Analysis]